Zhejiang Benli Technology Past Earnings Performance
Past criteria checks 4/6
Zhejiang Benli Technology's earnings have been declining at an average annual rate of -9.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 4.7% per year. Zhejiang Benli Technology's return on equity is 4.8%, and it has net margins of 8.7%.
Key information
-9.4%
Earnings growth rate
-18.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 4.7% |
| Return on equity | 4.8% |
| Net Margin | 8.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Zhejiang Benli Technology's (SZSE:301065) Performance Is Even Better Than Its Earnings Suggest
Nov 01
We Think You Should Be Aware Of Some Concerning Factors In Zhejiang Benli Technology's (SZSE:301065) Earnings
May 02Recent updates
Zhejiang Benli Technology's (SZSE:301065) Performance Is Even Better Than Its Earnings Suggest
Nov 01What Zhejiang Benli Technology Co., Ltd.'s (SZSE:301065) 42% Share Price Gain Is Not Telling You
Aug 08Zhejiang Benli Technology (SZSE:301065) Will Pay A Smaller Dividend Than Last Year
Jun 19Lacklustre Performance Is Driving Zhejiang Benli Technology Co., Ltd.'s (SZSE:301065) Low P/E
Jun 07We Think You Should Be Aware Of Some Concerning Factors In Zhejiang Benli Technology's (SZSE:301065) Earnings
May 02Earnings Not Telling The Story For Zhejiang Benli Technology Co., Ltd. (SZSE:301065) After Shares Rise 30%
Mar 08Revenue & Expenses Breakdown
How Zhejiang Benli Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 712 | 62 | 39 | 27 |
| 30 Jun 24 | 734 | 71 | 38 | 28 |
| 31 Mar 24 | 716 | 64 | 40 | 27 |
| 31 Dec 23 | 698 | 60 | 40 | 28 |
| 30 Sep 23 | 686 | 56 | 41 | 29 |
| 30 Jun 23 | 677 | 49 | 39 | 29 |
| 31 Mar 23 | 730 | 56 | 35 | 28 |
| 01 Jan 23 | 759 | 60 | 33 | 27 |
| 30 Sep 22 | 740 | 61 | 32 | 25 |
| 30 Jun 22 | 717 | 61 | 29 | 23 |
| 31 Mar 22 | 662 | 55 | 25 | 21 |
| 01 Jan 22 | 621 | 55 | 27 | 20 |
| 30 Sep 21 | 646 | 71 | 26 | 19 |
| 30 Jun 21 | 653 | 87 | 28 | 18 |
| 31 Mar 21 | 633 | 87 | 30 | 20 |
| 31 Dec 20 | 625 | 92 | 28 | 22 |
| 30 Sep 20 | 605 | 95 | 48 | 34 |
| 31 Dec 19 | 559 | 73 | 27 | 19 |
| 31 Dec 18 | 438 | 45 | 18 | 18 |
| 31 Dec 17 | 337 | 25 | 19 | 12 |
Quality Earnings: 301065 has high quality earnings.
Growing Profit Margin: 301065's current net profit margins (8.7%) are higher than last year (8.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301065's earnings have declined by 9.4% per year over the past 5 years.
Accelerating Growth: 301065's earnings growth over the past year (11.2%) exceeds its 5-year average (-9.4% per year).
Earnings vs Industry: 301065 earnings growth over the past year (11.2%) exceeded the Pharmaceuticals industry -1.2%.
Return on Equity
High ROE: 301065's Return on Equity (4.8%) is considered low.